MDS Virtual Congress 2020 Archives - Page 120 of 149

Risk of Hospital Admission in Patients with Parkinson’s disease Associated Psychosis (1991-2010)

C. Stang, M. Hajeb, E. Camerucci, P. Turcano, A. Mullan, P. Martin, V. Abler, M. Splett, N. Rashid, J. Bower, M. Mielke, R. Savica (Rochester, MN, USA)
Risk of Suicidal Ideation After Deep Brain Stimulation Surgery in Patients with Parkinson’s Disease

A. Seritan, J. Parad, S. Wang, J. Ostrem, A.M Iosif (San Francisco, CA, USA)
Robotic Assisted Arm Training in Parkinson’s disease rehabilitation: A pilot study

R. Yadav, S. Shukla (Etawah, India)
ROI based Machine Learning Classification Model for Spinocerebellar Ataxia type 12

S. Agrawal, M. Narang, P. Pankaj, A. Srivastava, S. Kumaran, R. Agrawal (New Delhi, India)
Role of Sex in Parkinson’s Disease Progression

E. Bayram, S. Eberly, D. Oakes, I. Litvan (La Jolla, CA, USA)
Rotenone exposure is associated with mitochondrial DNA (mtDNA) damage in humans

S. Goldman, C. Tanner, C. Gonzalez-Hunt, C. Meng, K. Comyns, M. Korell, L. Sanders (San Francisco, CA, USA)
Saccadic and Smooth Pursuit Derangements in Essential Tremor: A Video Oculography Study

T. Sahin, R. Yilmaz, M.C Akbostanci (Ankara, Turkey)
Safety and efficacy of focused ultrasound staged bilateral thalamotomy for Essential tremor

R. Martinez-Fernandez, J. Pineda-Pardo, J. Mañez-Miró, M. del Álamo, F. Hernandez-Fernandez, R. Rodriguez-Rojas, L. Guida, M. Matarazzo, L. Hermes-Gonzalez, L. Diaz-Fernandez, C. Ammann, L. Vela, J. Obeso (Móstoles, Spain)
Safety and efficacy of istradefylline, an adenosine A2A receptor antagonist, as a function of baseline dyskinesia (BL-dyskinesia) in Parkinson’s disease (PD): A pooled analysis of 4 studies

L. Elmer, K. Toyama, J. Parno, D. Braccia, R. Ristuccia, A. Mori (Toledo, OH, USA)
Safety and Tolerability of Burst Cycling Deep Brain Stimulation for Freezing of Gait in Parkinson’s Disease

W. Hu, J. Wang, R. Barmore, J. Melo Lobo, T. Tsuboi, A. Wang, A. Ramirez-Zamora, M. Okun, L. Almeida (Gainesville, FL, USA)